nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—nervous system—Gilles de la Tourette syndrome	0.0708	0.117	CbGeAlD
Epoprostenol—PTGIS—central nervous system—Gilles de la Tourette syndrome	0.0682	0.112	CbGeAlD
Epoprostenol—PTGER1—nervous system—Gilles de la Tourette syndrome	0.0659	0.108	CbGeAlD
Epoprostenol—P2RY12—nervous system—Gilles de la Tourette syndrome	0.0638	0.105	CbGeAlD
Epoprostenol—PTGER1—central nervous system—Gilles de la Tourette syndrome	0.0634	0.104	CbGeAlD
Epoprostenol—P2RY12—central nervous system—Gilles de la Tourette syndrome	0.0614	0.101	CbGeAlD
Epoprostenol—PTGIS—brain—Gilles de la Tourette syndrome	0.0541	0.0892	CbGeAlD
Epoprostenol—P2RY12—brain—Gilles de la Tourette syndrome	0.0488	0.0803	CbGeAlD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0421	0.107	CbGpPWpGaD
Epoprostenol—PTGIR—nervous system—Gilles de la Tourette syndrome	0.0407	0.067	CbGeAlD
Epoprostenol—PTGIR—central nervous system—Gilles de la Tourette syndrome	0.0392	0.0645	CbGeAlD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0387	0.0986	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0387	0.0986	CbGpPWpGaD
Epoprostenol—PTGIR—brain—Gilles de la Tourette syndrome	0.0311	0.0512	CbGeAlD
Epoprostenol—P2RY12—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00746	0.019	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00724	0.0185	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00693	0.0176	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00675	0.0172	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00672	0.0171	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00637	0.0162	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00637	0.0162	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00626	0.016	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00619	0.0158	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00619	0.0158	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00593	0.0151	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00576	0.0147	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00576	0.0147	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00576	0.0147	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00546	0.0139	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00546	0.0139	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—HDC—Gilles de la Tourette syndrome	0.00545	0.0139	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00537	0.0137	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0053	0.0135	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0053	0.0135	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00522	0.0133	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00494	0.0126	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00494	0.0126	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00467	0.0119	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00452	0.0115	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00439	0.0112	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00439	0.0112	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00416	0.0106	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00416	0.0106	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00409	0.0104	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00404	0.0103	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00404	0.0103	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00404	0.0103	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00404	0.0103	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00376	0.00958	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00376	0.00958	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00376	0.00957	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00346	0.00881	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00346	0.00881	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00286	0.00729	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00263	0.00671	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00263	0.00671	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00255	0.0065	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00248	0.00631	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00235	0.00598	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00235	0.00598	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00232	0.00591	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00231	0.00588	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00228	0.00581	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00228	0.00581	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00225	0.00573	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00213	0.00543	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00213	0.00543	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00213	0.00541	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00213	0.00541	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0021	0.00534	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00207	0.00528	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00207	0.00528	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00193	0.00491	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00193	0.00491	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00162	0.00412	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00149	0.00379	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00149	0.00379	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00147	0.00374	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00137	0.00349	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00135	0.00344	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00135	0.00344	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00133	0.00339	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00126	0.00321	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00126	0.00321	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00124	0.00315	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00122	0.00312	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00122	0.00312	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00114	0.0029	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00114	0.0029	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	0.00088	0.00224	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000868	0.00221	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000798	0.00203	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000798	0.00203	CbGpPWpGaD
